Pfizer and Bristol-Myers Seek Eliquis Approval, and 3 More Hot Stocks
Pfizer Inc. (NYSE:PFE): The Eliquis blood thinner, developed with Bristol-Myers (NYSE:BMY), was just as effective as the generic Warfarin at preventing blood clots and death in a trial of 5,400 patients who suffered from venous thromboembolism, or VTE. The two companies will now seek approval for to use Eliquis for treating VTE, taking on the competing Xarelto from Johnson & Johnson and Bayer, which is already approved.
News Corporation (NASDAQ:NWSA): Media analysts with both Lazard Capital and Deutsche Bank have initiated coverage of News’ spinoff 21st Century Fox (FOXA) with a Buy rating, while the sum-of-the-parts idea will be tested to see if the two companies can be worth more as separate entities. General Street consensus is that the growth potential and outlook for margins in the entertainment wing look more appealing than those of the new News Corp., though the latter’s cash pile of $2.6 billion opens the doors for some M&A activity.
Citigroup Inc. (NYSE:C): Citi has agreed to pay Fannie Mae a sum of $968 million to settle potential mortgage repurchase claims on 3.7 million mortgages sold between 2000 and 2012, with the bank expecting to report a mortgage repurchase reserve build of $245 million in the second quarter, consistent with its repurchase reserve builds in recent quarters.
Canadian Solar Inc. (NASDAQ:CSIQ): A deal to supply 91 MW worth of solar modules to Asia-based solar power provider Soleq Solar for Thai power plant projects has driven shares to new 52-week highs, up over 7.7 percent on Monday after healthy gains last week. Deliveries are already underway, and the project is anticipated to be completed by the fourth quarter.